10-Q · May 13, 2026
Curis, Inc. reported no revenue for Q1 2026, missing the analyst expectations of $2,092,000. The company's net loss was $24.2 million, resulting in an EPS of -$1.25, a significant increase from the previous year's loss…
Earnings analysis · 10-Q
CRIS earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement, or MD&A needed to assess current-quarter revenue, margins, EPS, working capital, and cash flow; those metrics are…
Read full summary
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement, or MD&A needed to assess current-quarter revenue, margins, EPS, working capital, and cash flow; those metrics are therefore unavailable. Liquidity improved through the August 2026 offering, which produced approximately $4.8 million of estimated net proceeds, but management expects the combined $9.9 million of cash and proceeds to fund operations only into the fourth quarter of 2026. The explicit going-concern conclusion, continuing funding needs, Nasdaq monitoring, and reverse-split liquidity concerns support a bearish assessment.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
$5.5M Public Offering Completed
The August 2026 Public Offering generated approximately $5.5 million of gross proceeds, before fees and offering expenses, including the issuance of 335,001 shares and pre-funded warrants for up to 3,398,333 shares.
-
Liquidity Supplemented by Financing
Management estimates approximately $4.8 million of net offering proceeds after placement-agent fees and other expenses, supplementing $5.1 million of cash and cash equivalents at June 30, 2026.
-
Disclosure Controls Remained Effective
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026, and reported no material control changes during the quarter.
What to watch
-
Going-Concern Doubt and Limited Runway
The company identified conditions raising substantial doubt about its ability to continue as a going concern. It stated that $5.1 million of existing cash plus approximately $4.8 million of offering proceeds should fund operations only into the fourth quarter of 2026, and that cash is insufficient to support operations beyond 12 months from the filing date.
-
Nasdaq Delisting Exposure
Nasdaq compliance remains vulnerable despite the company regaining compliance with the minimum bid-price requirement on July 24, 2026. The company is subject to a one-year Discretionary Panel Monitor and cannot receive additional compliance-plan time for deficiencies arising during that period.
-
Reverse Split May Reduce Liquidity
The July 6, 2026 1-for-20 reverse stock split may reduce trading liquidity and increase odd-lot ownership. The filing notes that odd lots are holdings of less than 100 shares and may involve higher transaction costs.
Management's outlook
No quantitative revenue or EPS guidance was provided in the supplied 10-Q text. Management states that $5.1 million of cash at June 30, 2026 plus approximately $4.8 million of net proceeds from the August 2026 Public Offering should fund operations into the fourth quarter of 2026.
Earlier filings 4
10-K · March 24, 2026
Curis (CRIS) is a clinical-stage biotech focused on emavusertib (IRAK4/FLT3 inhibitor) and is concentrating development on a Phase 1/2 PCNSL combination with ibrutinib and a Phase 2 CLL combination with zanubrutinib.…
10-K · March 16, 2021
Curis is an early-stage oncology biotech focused on developing CA-4948 (IRAK4 inhibitor) and CI-8993 (anti-VISTA antibody) while continuing to receive royalties and milestones from Genentech for Erivedge. The company…
10-Q · August 9, 2019
Curis reported Q2 2019 revenue of $2.094 million (down from $2.358 million a year earlier) and a GAAP net loss of $7.213 million (net loss per share $0.22). Operating loss narrowed to $6.141 million from $7.860 million…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.